Poston G J, Yao C Z, Upp J R, Alexander R W, Townsend C M, Thompson J C
Department of Surgery, University of Texas Medical Branch, Galveston 77550.
Pancreas. 1988;3(4):439-43. doi: 10.1097/00006676-198808000-00012.
We have previously shown that hamster H2T pancreatic ductal cancer has a receptor for vasoactive intestinal peptide (VIP) which is not present on a cell line of human pancreatic ductal cancer (MIA). The purpose of this study was to examine the effect of chronic administration of VIP on the growth of both H2T hamster pancreatic carcinoma and MIA human pancreatic carcinoma in vivo. The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days. Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content). The growth of MIA was studied in athymic Balb/c mice, one group of 10 received 0.1% BSA and the other 10 received VIP (1 nmol/kg), both three times a day by i.p. injection for 3 months. There was no difference in tumor growth rate between the two groups. Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice. We conclude that the differential response of hamster and human pancreatic cancer to VIP treatment may be due to the presence or absence of VIP receptors.
我们之前已经表明，仓鼠H2T胰腺导管癌有一种血管活性肠肽（VIP）受体，而人胰腺导管癌细胞系（MIA）上不存在这种受体。本研究的目的是检测长期给予VIP对体内H2T仓鼠胰腺癌和MIA人胰腺癌生长的影响。在仓鼠中研究了H2T的生长；一个由6只仓鼠组成的对照组接受盐水中0.1%的牛血清白蛋白（BSA），两个治疗组各有6只仓鼠，分别接受VIP（1和10 nmol/kg），均通过腹腔注射每天给药3次，持续35天。两种剂量的VIP均抑制了H2T肿瘤的生长（肿瘤面积、重量、DNA、RNA和蛋白质含量）。在无胸腺的Balb/c小鼠中研究了MIA的生长，一组10只接受0.1%的BSA，另一组10只接受VIP（1 nmol/kg），均通过腹腔注射每天给药3次，持续3个月。两组之间肿瘤生长速率没有差异。VIP治疗对仓鼠或小鼠的正常胰腺体重或大小没有任何影响。我们得出结论，仓鼠和人胰腺癌对VIP治疗的不同反应可能是由于VIP受体的存在或缺失。
